Form 8-K - Current report:
SEC Accession No. 0001723128-24-000030
Filing Date
2024-08-09
Accepted
2024-08-09 06:14:33
Documents
16
Period of Report
2024-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amrx-20240807.htm   iXBRL 8-K 31960
2 EX-99.1 amrx-q22024xex991ipx203app.htm EX-99.1 36270
3 EX-99.2 amrx-q22024ex992.htm EX-99.2 505052
7 amneala.jpg GRAPHIC 2670
  Complete submission text file 0001723128-24-000030.txt   748382

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amrx-20240807.xsd EX-101.SCH 1995
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amrx-20240807_lab.xml EX-101.LAB 21885
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amrx-20240807_pre.xml EX-101.PRE 12599
19 EXTRACTED XBRL INSTANCE DOCUMENT amrx-20240807_htm.xml XML 2729
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 241190319
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)